HIV infection
Conditions
Interventions
treatment group A:Yiaikang capsule
treatment group B:Jianaikang concentration pill
control group A:Yiaikang capsule analog agent
control group B:Jianaikang concentration pill simulant
Sponsors
The First Affiliated Hospital of Henan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) meet the diagnostic criteria for HIV infection; (2) CD4+T lymphocyte level 250 ~ 500 /ul; (3) accept HAART for more than one year; (4) conform to TCM syndrome differentiation standards; (5) aged 18 to 65 years male and female; (6) subjects voluntarily participated and informed consent.
Exclusion criteria
Exclusion criteria: (1) those who are participating in other clinical trials or have participated in other clinical trials within 3 months; (2) severe organic heart disease and severe arrhythmia.Abnormal liver function (Alt or ast); Abnormal renal function (serum creatinine was more than 1.5 times of normal value); Patients with active tuberculosis or undergoing antituberculosis treatment; Patients with haematological diseases; (3) those with tumors; (4) patients with severe mental and neurological diseases; (5) women who are pregnant or lactating, or who are preparing for pregnancy; (6) allergic constitution and allergic to experimental drugs; (7) those with a history of alcohol abuse (over 150ml per day) or with symptoms of alcohol dependence syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AIDS incidence rate;Time of onset of AIDS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms and signs of traditional Chinese Medicine;Occurrence of common diseases;CD4+ T-lymphocyte subsets count;CD8+ T-lymphocyte subsets count;Rate of CD4+/CD8+;WHOQOL-HIV- BREF;Report of outcome indicators in patients with measuring scale (PRO);HIV viral load;Medication compliance;interleukin-17;INF-?;interleukin-4;Tumor necrosis factor-a;Natural killer cell;CD4+CD45RA+ T lymphocytes;CD4+CD45RO+ T lymphocytes;CD4+CCR5(CC-chemokine receptor 5);CD4+CXCR4(CX-chemokine receptor 4);Expression of Toll-like receptor 4mRNA;T cell receptor gene diversity analysis; | — |
Countries
China
Contacts
Public ContactXU Liran
The First Affiliated Hospital of Henan University of Chinese Medicine
Outcome results
None listed